More articles from Current Drug Therapy

  • Dabigatran: Will it change clinical practice?
    Siddharth A. Wartak, MD and John R. Bartholomew, MD, FACC
    Cleveland Clinic Journal of Medicine October 2011, 78 (10) 657-664; DOI: https://doi.org/10.3949/ccjm.78a.11021

    This new oral anticoagulant has advantages over warfarin (Coumadin), but it is more expensive, which may pose a barrier to its wider use.

  • What is the optimal duration of bisphosphonate therapy?
    What is the optimal duration of bisphosphonate therapy?
    Susan M. Ott, MD
    Cleveland Clinic Journal of Medicine September 2011, 78 (9) 619-630; DOI: https://doi.org/10.3949/ccjm.78a.11022

    It is reasonable to stop bisphosphonates after 5 years of use and then to follow patients with markers of bone turnover.

  • Vancomycin: A 50-something-yearold antibiotic we still don’t understand
    Amy Schilling, PharmD, Elizabeth Neuner, PharmD and Susan J. Rehm, MD
    Cleveland Clinic Journal of Medicine July 2011, 78 (7) 465-471; DOI: https://doi.org/10.3949/ccjm.78a.10168

    To use vancomycin appropriately, we need to recognize its changing minimum inhibitory concentrations, select proper doses and dosing intervals, and know how to monitor its use.

  • Insulin treatment for type 2 diabetes: When to start, which to use
    Marwan Hamaty, MD, MBA
    Cleveland Clinic Journal of Medicine May 2011, 78 (5) 332-342; DOI: https://doi.org/10.3949/ccjm.78a.10051

    Many patients with type 2 diabetes eventually need insulin. This review addresses practical approaches.

  • Dronedarone for atrial fibrillation: How does it compare with amiodarone?
    Neelima Penugonda, MD, Adam Mohmand-Borkowski, MD and James F. Burke, MD
    Cleveland Clinic Journal of Medicine March 2011, 78 (3) 179-185; DOI: https://doi.org/10.3949/ccjm.78a.10049

    Dronedarone’s precise role is yet to be defined, but if it is as well tolerated as hoped, it may help clinicians pursue a rhythm control strategy more often.

  • MAO inhibitors: Risks, benefits, and lore
    Molly Wimbiscus, MD, Olga Kostenko, MD and Donald Malone, MD
    Cleveland Clinic Journal of Medicine December 2010, 77 (12) 859-882; DOI: https://doi.org/10.3949/ccjm.77a.09103

    Monoamine oxidase inhibitors were the first antidepressants introduced. Interest in their use is reviving.

  • Coenzyme Q10: A therapy for hypertension and statin-induced myalgia?
    Marcia Wyman, PharmD, Mandy Leonard, PharmD, BCPS and Thomas Morledge, MD
    Cleveland Clinic Journal of Medicine July 2010, 77 (7) 435-442; DOI: https://doi.org/10.3949/ccjm.77a.09078

    These supplements appear to be safe, but larger trials are needed to determine if they are truly effective.

  • Omeprazole and clopidogrel: Should clinicians be worried?
    Jeremiah P. Depta, MD and Deepak L. Bhatt, MD, MPH
    Cleveland Clinic Journal of Medicine February 2010, 77 (2) 113-116; DOI: https://doi.org/10.3949/ccjm.77a.09173

    The FDA has warned of a possible interaction between omeprazole (Prilosec) and clopidogrel (Plavix), but for the time being we should not change the way we manage patients.

  • Acetaminophen: Old drug, new warnings
    Amy Schilling, PharmD, Rebecca Corey, PharmD, BCPS, Mandy Leonard, PharmD, BCPS and Bijan Eghtesad, MD
    Cleveland Clinic Journal of Medicine January 2010, 77 (1) 19-27; DOI: https://doi.org/10.3949/ccjm.77a.09084

    Often, patients overdose because they take more than one acetaminophen product and are unaware that both products contain the drug.

  • Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
    Lawrence D. Lazar, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine December 2009, 76 (12) 707-714; DOI: https://doi.org/10.3949/ccjm.76a.09116

    Prasugrel (Effient) is faster and more consistent in its effects, but patients at high bleeding risk should still receive clopidogrel (Plavix).

Pages